Poliovirus immunity among pregnant females aged 15-44 years, Namibia, 2010.

BACKGROUND Poliovirus (PV) antibody seroprevalence studies assess population immunity, verify an immunization program's performance and vaccine efficacy, and guide polio eradication strategy. Namibia experienced a polio outbreak among adults in 2006, yet population seroimmunity was unknown. METHODS We tested 2061 specimens from Namibian pregnant females aged 15-44 years for neutralizing antibody to PV types 1-3 (PV1-3); all females were sampled during the 2010 National HIV Sentinel Survey. We determined the proportion of females seropositive for PV antibody by 5-year age strata, and analyzed factors associated with seropositivity, including age, gravidity, human immunodeficiency virus (HIV) infection status, residence, and antiretroviral treatment, by log-binomial regression. RESULTS The seroprevalence was 94.6% for PV1, 97.0% for PV2, and 85.1% for PV3. HIV-positive females had significantly lower seroprevalence than HIV-negative females for PV1 (91.8% vs 95.3%; P<.01) and PV3 (80.0% vs 86.1%; P<.01) but not for PV2 (96.4% vs 97.1%; P=.3). The prevalence ratio of seropositivity for HIV-positive females versus HIV-negative females was 0.95 (95% confidence interval [CI], .92-.98) for PV1, 0.99 (95% CI, .97-1.01) for PV2, and 0.92 (95% CI, .87-.96) for PV3. CONCLUSIONS Despite relatively high PV seroprevalence, Namibia might remain at risk for a PV outbreak, particularly in lower-seroprevalence populations, such as HIV-positive females. Namibia should continue to maintain high routine polio vaccination coverage.

[1]  M. Pallansch,et al.  Outbreak of type 1 wild poliovirus infection in adults, Namibia, 2006. , 2014, The Journal of infectious diseases.

[2]  Y. Maldonado,et al.  Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. , 2013, The Journal of infectious diseases.

[3]  M. Pallansch,et al.  An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Buja,et al.  Seroepidemiology of Polioviruses among University Students in Northern Italy , 2012, Clinical and Vaccine Immunology.

[5]  Y. Maldonado,et al.  Immunologic Response to Oral Polio Vaccine in Human Immunodeficiency Virus–infected and Uninfected Zimbabwean Children , 2012, The Pediatric infectious disease journal.

[6]  K. Wannemuehler,et al.  Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. , 2011, Vaccine.

[7]  M. Wenner,et al.  Conclusions and recommendations , 2010, Annals of the New York Academy of Sciences.

[8]  A. Fowlkes,et al.  Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya , 2009, BMC infectious diseases.

[9]  M. Bonnet,et al.  Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies. , 2009, Vaccine.

[10]  Namibia.  Namibia Demographic and Health Survey 2006-07 , 2008 .

[11]  R. Sutter,et al.  Poliovirus vaccine-live , 2008 .

[12]  M. Gomes,et al.  Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002 , 2007 .

[13]  H. Doerr,et al.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students , 2007, Medical Microbiology and Immunology.

[14]  H. Rebelo de Andrade,et al.  Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  Elizabeth Mason,et al.  WHO's strategy on Integrated Management of Childhood Illness. , 2006, Bulletin of the World Health Organization.

[16]  Outbreak of polio in adults--Namibia, 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[17]  Outbreak of type-1 wild poliovirus in adults, Namibia, 2006. , 2006, Releve epidemiologique hebdomadaire.

[18]  L. Veronesi,et al.  Status of immunity against poliomyelitis: a study among European and extra-European young immigrants living in Parma. , 2005, Acta bio-medica : Atenei Parmensis.

[19]  T. Shohat,et al.  Immune status to poliovirus among immigrant workers in Israel. , 2005, Preventive medicine.

[20]  F. Pregliasco,et al.  A seroepidemiologic survey of immunity against poliomyelitis in a group of HIV positive and HIV negative drug addicts , 1995, European Journal of Epidemiology.

[21]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[22]  A. Antoniadis,et al.  A seroprevalence study of poliovirus antibody in the population of northern Greece. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  M. Barbi,et al.  Prevalence of anti-poliovirus type 1, 2 and 3 antibodies in unvaccinated Italian travelers. , 2004, Journal of travel medicine.

[24]  Sti Surveillance.  Guidelines for conducting HIV sentinel serosurveys among pregnant women and other groups , 2004 .

[25]  H. D. de Melker,et al.  Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. , 2003, Vaccine.

[26]  M. Pallansch,et al.  Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children , 1991, The Lancet.

[27]  D. Gray,et al.  The Monitoring System , 1966 .